Deep TMS News - Get The Latest News On BrainsWay's Deep TMS

News & Events

November 28, 2022

BrainsWay Reports Open Market Stock Purchases by Two Board Members

BURLINGTON, Mass. and JERUSALEM, November 28, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

November 16, 2022

BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights

Conference call to be held today, November 16, 2022, at 8:30 AM ET                       ...

November 3, 2022

BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™

Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression Patients BURLINGTON,...

November 2, 2022

BrainsWay to Report Third Quarter Financial Results on November 16, 2022

BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

November 1, 2022

BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs

Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years BURLINGTON, Mass....

October 12, 2022

BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month

The sweepstakes aims to raise awareness of Deep TMS™ as a treatment option for mental health disorders...

October 11, 2022

BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments

BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

September 20, 2022

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

September 14, 2022

BrainsWay Announces Private Insurance Coverage from Cigna Corporation for OCD Treatment

Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive Disorder BURLINGTON,...

August 31, 2022

BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference

BURLINGTON, Mass. and JERUSALEM, August 31, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

August 29, 2022

BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression

Depression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company’s 9th FDA Clearance BURLINGTON,...

August 10, 2022

BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 14% Year-over-Year in Q2 2022 Conference call to be held today, August 10, 2022, at...

July 27, 2022

BrainsWay to Report Second Quarter Financial Results on August 10, 2022

BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

June 28, 2022

BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression

The Company’s Groundbreaking Deep TMS™ Treatment is Included in Israel’s Health Basket of Essential...

June 23, 2022

BrainsWay Donates $10,000 to Mental Health America in Support of Mental Health Awareness Month

BURLINGTON, Mass. and JERUSALEM, Israel, June 23, 2022 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”...

June 22, 2022

BrainsWay to Present at the H.C. Wainwright 1st Annual Mental Health Conference

BURLINGTON, Mass. and JERUSALEM, June 22, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

June 21, 2022

BrainsWay Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™

Highmark BCBS Covers 6.8 Million Members in Four States BURLINGTON, Mass. and JERUSALEM, June 21, 2022...

May 11, 2022

BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 30% Year-over-Year in Q1 2022 Conference call to be held today, May 11, 2022, at 8:30...